Table 1 Baseline demographic and clinical characteristics of study cohort
Number of participants, % (n=1080) | |
|---|---|
Sex | |
Female | 597 (55.3%) |
Male | 483 (44.7%) |
Location | |
Urban | 828 (76.7%) |
Rural | 252 (23.3%) |
Age | |
Age at study enrolment (yrs, median (IQR)) | 13 (11–16) |
Age at ART initiation (yrs, median (IQR))* | 9 (6–12) |
Mode of infection | |
Vertically infected (n,%) | 808 (74.8%) |
Sexually infected (n,%) | 272 (25.2%) |
Year of ART initiation | |
2000–2009 | 436 (40.4%) |
2010–2013 | 373 (34.5%) |
2014–2017 | 114 (10.6%) |
Data not available | 157 (14.5%) |
Baseline viral load | |
<50 copies/mL | 99 (9.2%) |
51–999 copies/mL | 401 (37.1%) |
≥1000 copies/mL | 378 (35.0%) |
Data not available | 202 (18.7%) |
Baseline CD4 count | |
<200 cells/mm3 | 205 (19.0%) |
200–349 cells/mm3 | 192 (17.8%) |
≥350 cells/mm3 | 515 (47.7%) |
Data not available | 169 (15.6%) |
Baseline WHO Clinical Stage | |
Stage I | 283 (26.2%) |
Stage II | 167 (15.5%) |
Stage III | 212 (19.6%) |
Stage IV | 29 (2.7%) |
Data not available | 388 (35.9%) |
Follow-up time | |
Study follow-up time since ART initiation (yrs, median (IQR))* | 7.2 (4.7–9.8) |